GENEVA--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY ® Vitreoretinal Cataract System ...
(RTTNews) - Eye care company Alcon Inc. (ALC) announced Monday that UNITY Vitreoretinal Cataract System or VCS and UNITY Cataract System or CS have received U.S. Food and Drug Administration's 510(k) ...
I reiterate a 'Strong Buy' rating for Alcon with a one-year price target of $115 per share, driven by new product pipelines and FDA clearances. Alcon's Unity VCS/CS systems received FDA clearance, set ...
“Alcon has a long legacy of advancing phaco and vitreoretinal technology for surgical ophthalmology. With UNITY VCS/CS, we are introducing more than a dozen innovations designed to transform surgical ...
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, announced results from time and motion studies demonstrating superior efficiency * with UNITY ® ...
Hosted on MSN
Alcon reaffirms $10.3B–$10.4B 2025 sales outlook as Unity VCS and new launches drive Q4 acceleration
CEO David Endicott pointed to building momentum in the second half of 2025, with particular strength in equipment and ocular health. Endicott highlighted, "the launch [of Unity VCS] is delivering on ...
Alcon ALC unveiled results from time and motion studies demonstrating superior efficiency with the UNITY Vitreoretinal Cataract System (VCS) for vitreoretinal and cataract surgery compared to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results